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5-Aminosalicylic acid inhibits stem cell function in human
adenoma-derived cells: implications for chemoprophylaxis
in colorectal tumorigenesis
Steven William Dixon 1,2, Tracey Jane Collard1, Eleanor May Harrisdotter Mortensson1, Danny Nigel Legge 1,
Adam Christian Chambers1, Alexander Greenhough 1,3, Tom Julian Creed2 and Ann Caroline Williams 1
BACKGROUND: Most colorectal cancers (CRC) arise sporadically from precursor lesions: colonic polyps. Polyp resection prevents
progression to CRC. Risk of future polyps is proportional to the number and size of polyps detected at screening, allowing
identification of high-risk individuals who may benefit from effective chemoprophylaxis. We aimed to investigate the potential of
5-aminosalicylic acid (5-ASA), a medication used in the treatment of ulcerative colitis, as a possible preventative agent for
sporadic CRC.
METHODS: Human colorectal adenoma (PC/AA/C1, S/AN/C1 and S/RG/C2), transformed adenoma PC/AA/C1/SB10 and carcinoma
cell lines (LS174T and SW620) were treated with 5-ASA. The effect on growth in two- and three-dimensional (3D) culture, β-catenin
transcriptional activity and on cancer stemness properties of the cells were investigated.
RESULTS: 5-ASA was shown, in vitro, to inhibit the growth of adenoma cells and suppress β-catenin transcriptional activity.
Downregulation of β-catenin was found to repress expression of stem cell marker LGR5 (leucine-rich G protein-coupled receptor-5)
and functionally suppress stemness in human adenoma and carcinoma cells using 3D models of tumorigenesis.
CONCLUSIONS: 5-ASA can suppress the cancer stem phenotype in adenoma-derived cells. Affordable and well-tolerated, 5-ASA is
an outstanding candidate as a chemoprophylactic medication to reduce the risk of colorectal polyps and CRC in those at high risk.
British Journal of Cancer (2021) 124:1959–1969; https://doi.org/10.1038/s41416-021-01354-5
BACKGROUND
Colorectal cancer (CRC) is one of the most common malignancies
worldwide and, despite advances in treatment, is the second most
common cause for cancer-related mortality.1 Of concern, the
incidence of CRC appears to be rising in adults under the age of
50 years.2,3 CRC derives from pre-neoplastic precursor lesions—
polyps—which can be resected before malignant transformation.
Accordingly, many countries have employed national screening
programmes that allow identification of polyps and cancers at early
stages when they are more amenable to curative treatment. These
screening programmes also allow identification of individuals at high
risk of CRC: in the recent joint British Society of Gastroenterology/
Association of Coloproctology of Great Britain and Ireland/Public
Health England guidelines, individuals with high-risk findings are
offered further surveillance colonoscopy (high-risk findings are
defined by the presence of either (a) two or more polyps (excluding
diminutive hyperplastic rectal polyps 1–5mm), of which one polyp is
≥10mm or (b) ≥5 polyps of any size).4 Despite this, there is currently
no chemoprophylaxis that is offered to reduce the risk of further
polyps or CRC for these individuals.
Aspirin has demonstrated promise as a chemoprophylactic drug
in this context; several clinical trials have reported a reduction in
adenoma number with regular aspirin use.5,6 Most recently, the
seAFOod (Systematic Evaluation of Aspirin and Fish Oil) polyp
prevention trial recruited patients with high-risk endoscopic
findings from the English Bowel Cancer Screening Programme
and reported reduced number of polyps in the aspirin-treated
group at follow-up colonoscopy (although the adenoma detection
rate was not significantly reduced).7 Further, clinical trials have
demonstrated reduced colorectal polyp burden in patients with
the hereditary cancer syndrome Familial Adenomatous Polyposis
and halved the incidence of CRC in patients with Lynch syndrome
following aspirin use.8 This has resulted in the recent recommen-
dation by the National Institute of Clinical Excellence endorsing
the prescription of prophylactic aspirin for Lynch syndrome
mutation carriers.9 However, aspirin is associated with an
increased risk of bleeding, exemplified by the findings of two
recent, large randomised controlled trials.10,11 The ARRIVE (Aspirin
to Reduce Risk of Initial Vascular Events) trial reported that 100mg
aspirin daily doubled the risk of gastrointestinal bleeding (hazard
ratio (HR) 2.11, 95% confidence interval (CI) 1.36–3.28),10 similar to
that reported in the ASPREE trial (HR 1.87, 95% CI 1.32–2.66).11 The
ASPREE (Aspirin in Reducing Events in the Elderly) trial also reported
that the risk of intracranial bleeding was increased by 50% in healthy
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adults over 70 years old (HR 1.5, 95% CI 1.11–2.02).11 Consequently,
aspirin may not be a suitable chemoprophylactic drug in all patients
and certainly the benefit and harm needs to be carefully assessed
before use.12
5-Aminosalicylic acid (5-ASA) is a non-steroidal anti-inflamma-
tory drug structurally similar to aspirin which is commonly
prescribed to induce and maintain remission in chronic idiopathic
inflammatory bowel disease (IBD). Conventional subclassification
of IBD distinguishes two phenotypically categorised conditions:
ulcerative colitis (UC) and Crohn’s disease (CD). UC and CD are
both associated with an increased risk of CRC: the so-called colitis-
associated cancer (CAC).13,14
Although a complete understanding of the anti-inflammatory
mechanisms of 5-ASA is lacking, existing data imply that
5-ASA has efficacy in suppressing multiple pro-inflammatory
pathways: 5-ASA has been demonstrated to antagonise several
pro-inflammatory mediators including interferon-γ,15 tumour
necrosis factor-α15,16 and nuclear factor-κB,16,17 which may be,
at least in part, due to agonism of peroxisome proliferator-
activated receptor-γ (PPARγ).18 Information from epidemiology
studies is limited, but early observational data indicated that 5-
ASA reduced the risk of CAC,19 although a 2012 meta-analysis
reported a protective effect in clinic-based studies with no effect
in population-based studies.20 However, the two most-recent
meta-analyses by Qiu et al.21 and Bonovas et al.22 reported dose-
dependent protective effects of oral mesalazine across a range
of study designs, including pooled analysed of population-
based studies, in UC. Accordingly, the European Crohn’s and
Colitis Organisation have recommended lifelong oral 5-ASA
as chemoprophylaxis against CAC.23 Importantly, 5-ASA is well-
tolerated, is not associated with increased risk of bleeding
and is affordable for health providers. However, it remains
unknown whether 5-ASA confers a reduced risk of developing
sporadic CRC.
The mechanisms underpinning the apparent antineoplastic
activity of 5-ASA in CAC have not been fully elucidated, but
existing data from models of CRC have suggested that 5-ASA may
suppress Wnt/β-catenin through multiple mechanisms including
those implicated in its anti-inflammatory role including induction
of PPARγ;18,24 suppression of the cyclo-oxygenase-2/prostaglandin
E2 (PGE2) axis;
25 post-translational modification of the β-catenin
phosphatase protein phosphatase 2A.26 5-ASA may also promote
membranous sequestration of β-catenin through N-glycosylation
of and membranous translocation of E-cadherin;27 negative
regulation of the serine/threonine protein kinase PAK1;28 upregu-
lation of µ-protocadherin.29 Importantly, mutations resulting
in upregulated Wnt/β-catenin signalling are among the first
observed in colorectal adenomas and have been demonstrated as
being sufficient for early adenoma formation.30 Evidence that
5-ASA inhibits the β-catenin signalling in adenomas comes from
immunohistochemical analysis as part of the German 5-ASA Polyp
Prevention Trial: Munding et al.31 reported reduced expression of
β-catenin in adenomas from patients taking 1 g 5-ASA/day.
However, to date, these results have not been validated either
in vitro or in vivo in human adenoma, and the effect of 5-ASA on
adenoma growth is unknown. Further, given that Wnt/β-catenin
signalling is important for the maintenance of the colonic stem
compartment,32 we hypothesised that suppression of dysregu-
lated Wnt/β-catenin may suppress the stem phenotype, which,
crucially, may prevent adenoma formation and progression in
sporadic disease.
While the effect of 5-ASA on the growth of carcinoma-derived
cells in vitro has been described,33–38 no such data exist for cells
derived from colonic adenomas. In this study, we aimed to
establish the effect of 5-ASA on Wnt/β-catenin and stem cell
phenotype in human adenoma using adenoma-derived cells in
two-dimensional (2D) and three-dimensional (3D) models of
tumorigenesis in order to understand whether 5-ASA may be an
effective chemoprophylactic drug for individuals at high risk of
sporadic CRC.
METHODS
Cell lines and culture
The colorectal adenoma-derived cell lines PC/AA/C1, S/AN/C1
and S/RG/C2 and the transformed adenoma-derived cell line
PC/AA/C1/SB10 used in these experiments were established
in this laboratory, their derivation and characterisation have
been previously described.39–41 Growth medium was Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco; Thermo Fisher
Scientific, MA, USA) supplemented with 20% foetal bovine serum
(FBS), 1 µg/mL hydrocortisone sodium succinate (Sigma-Aldrich;
Merck, MO, USA), 0.2 U/mL insulin (Sigma-Aldrich; Merck, MO,
USA), 2 mM glutamine (Gibco; Thermo Fisher Scientific, MA, USA),
100 U/mL penicillin and 100 μg/mL streptomycin (Gibco; Thermo
Fisher Scientific, MA, USA). The CRC-derived cell lines LS174T and
SW620 were obtained from American Type Culture Collection
(Rockville, MD, USA) were cultured in DMEM supplemented with
10% FBS, 2 mM glutamine, 100 U/mL penicillin and 100 U/mL
streptomycin. All cell lines were routinely assessed for microbial
contamination (including mycoplasma) and characterised using
an in-house panel of cellular and molecular markers to check
that cell lines have not been cross-contaminated (every
3–6 months; data not shown). Stocks were securely catalogued
and stored, and passage numbers strictly adhered to prevent
phenotypic drift.
Treatments
5-ASA (Sigma-Aldrich; Merck, MO, USA) was dissolved in culture
media, pH balanced to 7.35–7.45, sterile-filtered and supplemented
with HEPES buffer solution 1M (Sigma-Aldrich; Merck, MO, USA)
(20 µL per 1mL 5-ASA solution).
All cell lines were seeded into 25 cm2 tissue culture flasks
(T25; Corning, NY, USA): all adenoma-derived cell lines were
seeded at 2 × 106 cells/flask (except PC/AA/C1, seeded at 4 × 106
cells/flask), transformed adenoma and CRC-derived cell lines at
1 × 106 cells/flask. Seeding densities were calculated so that all
cell lines were 70% confluent when treated with 5-ASA. After 72 h,
the culture media were replaced by 20–40 mM 5-ASA/culture
media solution. At 24, 48, and 72 h after the addition of 5-ASA,
floating cells were collected, attached cells were trypsinised and
both were counted in triplicate for each condition.
Immunoblotting
Whole-cell lysates were prepared in situ, on ice and analysed by
western blotting as previously described42 using antibodies to the
following: AXIN-2 (2151, Cell Signaling, MA, USA, 1:1000), β-catenin
(9587, Cell Signaling, MA, USA, 1:5000), active-β-catenin (05-665,
Millipore, Sigma, MA, USA, 1:1000), c-MYC (SC-40, Santa Cruz
Biotechnology, CA, USA, 1:200), LEF-1 (2230, Cell Signaling, MA,
USA, 1:1000) and LGR5 (Ab75850, Abcam, Cambridge, UK, 1:1000).
Equal loading was confirmed using β-actin (A5316, Sigma-Aldrich,
Merck, MO, USA. 1:1000) or α-tubulin (T9026, Sigma-Aldrich,
Merck, MO, USA. 1:10,000).
TOPflash reporter assay
Cells were treated with 5-ASA 24 h after transfection with
TOPflash/FOPflash and SV40-Renilla plasmids as previously
described43 using the Promega Dual Luciferase Reporter Assay
System (Promega, WI, USA) according to the manufacturer’s
instructions. FOPflash reporter with mutated TCF consensus sites
was used to control for non-specific output. Luminescence was
measured at 560 nm using a Modulus luminometer (Turner
Biosciences, CA, USA).
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Cells were transfected using Lipofectamine RNAiMAX (Invitrogen,
Thermo Fisher Scientific, MA, USA), according to the manufac-
turer’s protocol, with small interfering RNAs (siRNAs, final
concentration 50 nM; Dharmacon, Horizon Discovery, Cambridge,
UK) targeting LEF-1, or a negative control, for which four different
siRNA sequences were pooled.44 Cells were incubated overnight at
37 °C before medium changing. Samples were prepared 72 h after
transfection.
Spheroid formation assay
Spheroids formed from adenoma- and carcinoma-derived cells
were grown using an adapted protocol from the original Sato
paper.45 Cells were resuspended in Matrigel (Corning, NY, USA)
as a single-cell suspension and seeded into 24-well plates
(Corning, NY, USA) as described previously.46 The Matrigel
hemispheres were allowed to polymerise before being sub-
merged in advanced DMEM:F12 (Gibco, Thermo Fisher Scientific,
MA, USA) supplemented with 0.1% bovine serum albumin
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Fig. 1 5-Aminosalicylic acid inhibits the growth of human colonic adenoma cells as well as carcinoma cell lines in two-dimensional
culture. a Graphs show attached cell yield and the number of floating cells as a proportion of total cell yield of three adenoma-derived cell
lines (PC/AA/C1, S/AN/C1 and S/RG/C2), left, transformed adenocarcinoma cells (PC/AA/C1/SB10) and two CRC-derived cell lines (LS174T and
SW620), right, 24, 48 and 72 h after treatment with 20 and 40mM 5-ASA. Mean ± SEM; n= 3. One-way ANOVA with Bonferroni post-test, *p <
0.05; **p < 0.01; ***p < 0.001. b Graphs show attached cell yield and percentage of floating cells of (i) PC/AA/C1 and (ii) S/RG/C2; after
treatment with 40mM 5-ASA and 10 µM Q-VD-Oph or DMSO, cells were harvested and counted at 72 h. Mean ± SEM; n= 3. One-way ANOVA
with Bonferroni post-test, **p < 0.01; ***p < 0.001.
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(Sigma-Aldrich, Merck, MO, USA), 2 mM glutamine (Gibco,
Thermo Fisher Scientific, MA, USA), 10 mM HEPES (Sigma-
Aldrich, Merck, MO, USA), 100 U/mL penicillin and 100 U/mL
streptomycin (Gibco; Thermo Fisher Scientific, MA, USA), 1% N2
(Thermo Fisher Scientific, MA, USA), 2% B27 (Thermo Fisher
Scientific, MA, USA) and 0.2% N-acetylcysteine (Sigma-Aldrich,
Merck, MO, USA). For spheroid culture of PC/AA/C1 adenoma-
derived cells, the spheroid medium was further supplemented
with human epidermal growth factor (Peprotech, London, UK),
50 ng/mL. The culture media were refreshed twice weekly over
the course of 21 days in culture. Wells were imaged as Z-stacks
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software (both Leica Microsystems, Wetzlar, Germany) on days 7,
11, 14, 18 and 21. Images acquired were analysed using MATLAB
R2015a software (MathWorks, MA, USA).
Quantitative PCR (qPCR)
Total RNA was extracted from spheroids using TRI-reagent (Sigma-
Aldrich, Merck, MO, USA); a RNeasy mini kit (Qiagen, Hilden,
Germany) was utilised according to the manufacturer’s protocol
with an additional on-column DNase digestion step (RNase-Free
DNase Set; Qiagen, Hilden, Germany). Complementary DNA
synthesis was synthesised from 2 µg RNA, using the RNA-
dependent DNA polymerase, Moloney murine leukaemia virus
reverse transcriptase (Promega WI, USA). The samples were
diluted to a final concentration of 10 ng/µL. Following optimisa-
tion of primers and ensuring the annealing temperature provided
~100% amplification efficiency per cycle (data not shown), qPCR
was performed, as previously described,47 using SYBR Green PCR
mix (Qiagen, Hilden, Germany) and the following Qiagen
QuantiTect primers, LGR5 (cat. no. QT00027720) and CD133
(cat. no. QT00075586), with gene expression normalised inter-
changeably with both housekeeping genes TATA-binding protein
(TBP; cat. no. QT00000721) or hypoxanthine phosphoribosyl
transferase (HPRT; cat. no. QT00059066). Amplification data were
analysed using MxPro software version 4.10 (Agilent Technologies,
CA, USA).
Statistical analysis
All statistical analysis was performed using GraphPad Prism
software, student edition (GraphPad Software, California, USA).
P values were determined using either one-sample t test or one-
way analysis of variance testing with Bonferroni post-test. Results
are expressed as mean values ± SEM or ±SD where specified.
RESULTS
5-ASA suppresses the growth of adenoma- and CRC-derived cells
in vitro
Three adenoma-derived cell lines (PC/AA/C1, S/AN/C1 and S/RG/C2)
were seeded in T25 flasks for 72 h before treatment with 20 or
40mM 5-ASA (consistent with concentrations used previously33–38)
and the attached cell yield and floating cells counted after 24, 48
and 72 h (Fig. 1a). This experiment was also carried out in the
transformed adenoma cell line PC/AA/C1/SB10 and two CRC cell
lines (LS174T and SW620, Fig. 1a). 5-ASA inhibited the number of
attached cells in all adenoma-derived cell lines treated with either
20 or 40mM 5-ASA. Of interest, the adenoma-derived cell lines were
as sensitive to 5-ASA treatment as the tumorigenic cell lines (Fig. 1a).
In two of the three adenoma-derived cell lines, there was a
significant induction of floating cells 72 h after 40 mM 5-ASA
treatment, indicative of cell death. However, the reduction in
cell yield on treatment with 5-ASA could not be explained by
induction of cell death alone; in support of this, blocking
apoptosis with the pan-caspase inhibitor (Q-VD-OPh) did not
rescue the reduction in cell yield on 40 mM 5-ASA treatment
(Fig. 1b). Furthermore, although 5-ASA induced apoptosis in
cancer-derived cells LS174T, blocking it also had no effect on the
inhibition of cell yield when treated with 40 mM 5-ASA
(Supplementary Figure 1A); this is consistent with 5-ASA
inducing growth inhibition in the cancer cells as previously
reported.33–38 Taken together, these results show that 5-ASA
causes growth inhibition in both the colorectal adenoma- and
carcinoma-derived cells.
5-ASA downregulates Wnt/β-catenin signalling in human
adenoma and carcinoma cells
To measure the effect of 5-ASA on β-catenin/TCF-mediated
transcription activity in adenoma-derived cells, we treated PC/
AA/C1 (APC mutant) adenoma-derived cells with 5-ASA after
transfection with TOPflash and FOPflash reporter plasmids and
compared it to LS174T (β-catenin mutant) carcinoma-derived cells.
These cell lines were chosen as representative of tumours with
disrupted β-catenin signalling, important for the initiation of
colorectal carcinogenesis. At 24 h treatment, 40 mM 5-ASA
TOPflash activity was significantly suppressed (Fig. 2a, b, results
for the transformed adenoma-derived cells are shown in
Supplementary Figure 1B). A similar, but not statistically significant
trend was observed for cells treated with 20mM 5-ASA.
Interestingly, total cellular β-catenin levels and active depho-
sphorylated β-catenin were unchanged on western blots after 5-
ASA treatment in all cell lines (Fig. 2c and Supplementary Figure
2A, C). Next, we investigated β-catenin target expression after
treatment with 5-ASA (Fig. 2e and Supplementary Figure 2B, D).
Accordingly, known β-catenin-regulated proteins AXIN-2, c-MYC
and LEF-1 were downregulated by 20 and 40mM 5-ASA in both a
dose- and time-dependent manner with the most marked effects
observed at the higher dose at the 72 h time point (Fig. 2e and
Supplementary Figure 2B, D).
5-ASA reversibly suppresses expression of the stem-marker LGR5
in colorectal adenoma and carcinoma cells
LGR5 (Leucine Rich Repeat Containing G Protein-Coupled
Receptor 5) is an established marker of crypt-base stem cells.48
LGR5 expression is frequently expressed in adenoma and tumour
metastases but expression in primary CRC is variable49 (Fig. 3a).
Western blots show that 5-ASA suppresses expression of LGR5 in
2/3 adenomas, the transformed adenoma and both CRC-derived
cells, over a 72-h period (Fig. 3b). Because LGR5 is a β-catenin-
regulated gene, we hypothesised that the effect of 5-ASA would
be reversible, important for the maintenance of tissue home-
ostasis in the surrounding colonic epithelium. To determine
whether expression of LGR5 recovered on removal of 5-ASA, PC/
AA/C1 adenoma cells were treated with 5-ASA for 72 h before
Fig. 2 5-ASA suppresses β-catenin/TCF transcriptional activity. a, b TOPflash reporter assay at 24 h after 20 and 40mM 5-ASA. a PC/AA/C1
adenoma and b LS174T CRC-derived cells. Mean ± SEM; n= 3; *p < 0.05; **p < 0.01 c (i) Western blots of PC/AA/C1 and LS174T at 24, 48 and 72
h after treatment with 20 and 40mM 5-ASA showing expression of active dephosphorylated and total β-catenin protein; α-tubulin was used as
the loading control. (ii) Densitometry graphs show the fold change of active dephosphorylated β-catenin protein as a ratio of total β-catenin
expression over the 72-h period. Expression is normalised to the respective control. Data are presented as the mean ± SEM of three
independent experiments. n= 3. One sample t test was used to determine statistical significance. d Western blot of LEF-1 expression in PC/
AA/C1 and LS174T cells to determine the specificity of the LEF-1 antibody. The expression level of LEF-1 was measured by western blotting 72
h after transfection with a LEF-1 SMARTpool siRNA or negative control. The results are representative of three independent experiments. β-
Actin was used as the loading control. e (i) Western blot showing PC/AA/C1 and LS174T cells after 24, 48 and 72 h after treatment with 20 and
40mM 5-ASA. Wnt/β-catenin target proteins AXIN-2, c-MYC and LEF-1 are all downregulated with 5-ASA, with the most marked phenotype
observed at 72 h. β-Actin was used as the loading control. (ii) Densitometry graphs show the expression change of AXIN-2, c-MYC and LEF-1 as
a fold of the loading control at the 72-h timepoint. Expression is normalised to the respective control. Data are presented as the mean ± SEM
of three independent experiments. n= 3. One sample t test was used to determine statistical significance. *p < 0.05; **p < 0.01; ***p < 0.001.
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washing the cells and culturing for a further 3 days without 5-ASA.
Western blots demonstrated that re-expression of LGR5 was
noted within 12 h of stopping 5-ASA treatment in PC/AA/C1 cells
(Fig. 3c) with expression returning to baseline 48 h after stopping
treatment.
Low-dose 5-ASA reduces the ability of PC/AA/C1 cells to form
spheroids
LGR5+ stem cells form spheroid structures when grown in
extracellular matrix gels such as Matrigel, complete with
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in the gastrointestinal tract in vivo.45 As such, the ability of cells to
form spheroids from single-cell suspensions is considered an assay
of stemness.50
To establish whether 5-ASA could inhibit stem cell function, PC/
AA/C1 cells were seeded as a single-cell suspension into Matrigel.
As PC/AA/C1 cells were more sensitive to 5-ASA in 3D culture than
2D culture, they were treated with 1–5mM 5-ASA at the time of
seeding. 5 mM 5-ASA treatment was sufficient to significantly
block spheroid formation as well as growth of the adenoma-
derived cells (Fig. 4); there were significantly fewer spheroids after
7 days in 3D culture (Fig. 4a). In addition, spheroid size analysis
showed that 5-ASA treatment resulted in significantly smaller
spheroids after 21 days in culture (Fig. 4b–e). Similar findings were
noted for LS174T-derived CRC spheroids (Fig. 4f–i). Furthermore,
the messenger RNA (mRNA) expression of stem cell-associated
proteins LGR5 and CD133 was significantly decreased in the 2 and
5mM treated PC/AA/C1 and LS174T cells (Fig. 4j, k).
Importantly, when these experiments were repeated with 5-ASA
removed from the culture media at day 7, the growth inhibitory
effect on the PC/AA/C1 spheroids was sustained for a further
14 days in culture (Fig. 5a–d). Similar results were obtained for
LS174T CRC-derived spheroids (Fig. 5e–h). This finding further
suggests that 5-ASA suppresses the stem cell potential of the cells,
as both the number and the growth of the spheroids was unable
to fully recover to that of the untreated spheroids once the 5-ASA
is removed.
DISCUSSION
The results presented here provide new insights into the effect of
5-ASA, an affordable and well-tolerated drug, on the growth and
stemness potential of adenoma-derived cells in vitro. Important
for use in a cancer prevention setting, this is the first report to
document the effect of 5-ASA on adenoma-derived spheroids in
3D culture. 3D cell culture using spheroids is a useful model for
studying stem function; this is exemplified by elegant work from
the Sato group who generated a ‘library’ of spheroids derived
from colorectal adenoma and carcinomas and demonstrated
that not only did niche dependency decrease along the
adenoma–carcinoma sequence, but that spheroids reproduced
the histopathological grade and differentiation capacity of their
parental tumours both in vitro and as xenografts.51 Our data
demonstrated that 5-ASA consistently negatively regulated Wnt/β-
catenin activity and target gene expression, directly antagonising
a key signalling pathway of the colonic stem compartment.
Further, for the first time, 5-ASA was demonstrated to negatively
regulate expression of the stem cell marker LGR5 (and stem-
associated protein CD133). In addition, by blocking the formation
of adenoma-derived spheroids, 5-ASA was shown to functionally
suppress stemness.
Targeting adenoma cells with stem cell properties is
important because colorectal tumorigenesis is believed to be
initiated and driven by a subpopulation of cells with properties
of stemness—cancer stem cells—typified by asymmetric cell
division and slow cell turnover making them resistant to
traditional chemotherapeutics.52 Lineage-tracing experiments
have demonstrated that LGR5+ cells act as stem cells in mouse
adenoma and genetic tracing of LGR5+ clones in tumour
xenografts derived from human CRC organoids have demon-
strated that these cells have the ability to generate both
differentiated cells and self-renew.53 Further, LGR5+ cells drive
adenoma growth in mouse models54 and promote adenoma cell
survival in human adenoma.49 Baker et al.48 demonstrated using
in situ hybridisation that LGR5 expression is increased in
adenomas with expression throughout the adenomatous gland,
with a heterogeneous distribution and loss of stem hierarchy
observed in normal mucosa. Because LGR5 is a ‘Wnt
amplifier’55,56 expansion of LGR5+ cells may be a key step in
allowing cells without permissive mutations in other pro-
oncogenic signalling pathways to expand, driving the formation
of adenomas. Thus, it is possible that suppression of LGR5 may
suppress the stem potential of adenoma cells and may prevent
adenoma formation. Importantly, suppression of β-catenin
transcriptional activity and spheroid formation was demon-
strated at 5-ASA concentrations that are achievable with
available 5-ASA preparations: oral 5-ASA preparations equivalent
to 2 g/day achieve luminal concentrations of 12–22.7 mM.57 This
corresponds with observational epidemiological data suggest-
ing that 5-ASA >1.2 g/day is protective against CAC.21
How relevant 5-ASA-mediated negative regulation of LGR5 is for
established CRC remains less clear. While LGR5 is commonly
expressed/overexpressed in adenomas,48 expression is frequently
low/absent in CRCs before re-expression in metastatic deposits;49
indeed, LGR5+ cells appear to be important in metastatic
progression.58 As summarised by Morgan et al.,59 there is
abundant contradictory data on the role of LGR5 in CRC. This
may be explained, at least in part, by plasticity exhibited by CSCs.
Shimokawa et al.53 recently demonstrated that LGR5+ carcinoma
cells differentiated into both LGR5+KRT20− and LGR5−KRT20+
daughters, and that selective ablation of LGR5 (using a CRISPR-
Cas9 system) resulted initially in tumour regression followed by re-
expression of LGR5 and recovery of tumour growth. In this
context, using 5-ASA to prevent the re-expression of LGR5 may
not only prevent tumour formation and potentially recurrence
after treatment but may also improve the efficacy of conventional
therapies, improving the prognosis of patients with CRC.
Importantly in the 3D cultures, it was possible to demonstrate
that the growth inhibitory effect of 5-ASA on the PC/AA/
C1 spheroids was sustained for a further 14 days in culture after
removal of the drug, suggesting that continuous administration of
5-ASA may not be necessary for either chemoprophylaxis or
therapy.
5-ASA is an affordable and well-tolerated drug with decades
of clinical experience in the treatment of UC, making it an
Fig. 3 5-ASA suppresses the expression of the stem-marker LGR5. a Endogenous levels of LGR5 expression in a panel of colorectal
adenoma- and carcinoma-derived cell lines. PC/AA/C1, S/AN/C1, S/RG/C2 colorectal cells, PC/AA/C1/SB10 transformed adenocarcinoma cells,
HT29, HCA7, HCT116, HCT15, SW480, SW620, LOVO, LS174T colorectal adenocarcinoma cells and SW837 and SW1463 rectal adenocarcinoma
cells were grown to ~70% confluence before collection of total protein for western blot analysis. α-Tubulin used as the loading control.
b (i) Western blot analysis demonstrating downregulation of LGR5 in three adenomas (PC/AA/C1, S/AN/C1 and S/RG/C2), left, transformed
adenocarcinoma cells (PC/AA/C1/SB10) and two CRC-derived cell lines (LS174T and SW620), right, 24, 48 and 72 h after treatment with 20 and
40mM 5-ASA. β-Actin was used as a loading control. LGR5 is highly glycosylated59, leading to the different banding patterns seen in the
different cell lines. (ii) Densitometry graphs show the expression change of LGR5 as a fold of the loading control at the 72h timepoint.
Expression is normalised to the respective control. Data are presented as the mean ± SEM of three independent experiments. n= 3. One
sample t test was used to determine statistical significance. *p < 0.05; **p < 0.01. c (i) Western blots of LGR5 expression in PC/AA/C1 adenoma
cells demonstrating downregulation of LGR5 after commencing treatment with 20 and 40mM 5-ASA, but a subsequent reversal of this
regulation once 5-ASA was withdrawn. β-Actin was used as a loading control. (ii) Western blot analysis of LGR5 expression in the 12 h after
stopping 5-ASA treatment. β-Actin was used as a loading control.
5-Aminosalicylic acid inhibits stem cell function in human. . .
SW Dixon et al.
1965
outstanding candidate as a chemoprophylactic agent for patients
at risk of CRC. Perhaps, surprisingly, for a drug that has been
known for some time to suppress β-catenin activity in CRC cells,
there have been a lack of clinical trials to assess the efficacy of
5-ASA in the prevention of sporadic CRC. In targeting the
stemness potential of adenoma-derived cells, results from this
study provide new evidence to support the use of 5-ASA for the
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evidence from other studies, including analysis of the effect of
5-ASA in patient samples,31 we believe that robust clinical trials
are now required to understand whether these findings translate
into a reduction in adenoma burden in at-risk individuals.
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Fig. 4 5-ASA reduces the ability of PC/AA/C1 adenoma and LS174T carcinoma cells to form spheroids. a–e PC/AA/C1 human adenoma-
derived cells. a Mean number of spheroids in each well 7 days after culture. n= 3 ± SEM; *p < 0.05. b Mean log spheroid area over 21 days in
culture. c Log spheroid area of spheroids at day 21, demonstrating distribution of spheroid size. n= 1 ± SD representative of n= 3. d Mean log
spheroid area of spheroids at day 1. n= 3 ± SEM; *p < 0.05; **p < 0.01. e Representative images of PC/AA/C1-derived spheroids at day 21.
Images acquired using Leica DM16000 microscope, ×5 lens with the Leica LAS-X software. Images were processed using MatLab software.
f–i LS174T human carcinoma-derived cells. fMean number of spheroids in each well 7 days after culture. n= 3 ± SEM; ***p < 0.001. g Mean log
spheroid area over 21 days in culture. h Log spheroid area of spheroids at day 21, demonstrating distribution of spheroid size. n= 1 ± SD
representative of n= 3. i Mean log spheroid area of spheroids at day 21. n= 3 ± SEM; **p < 0.01; ***p < 0.001. j–k Quantitative PCR (QPCR)
mRNA analysis of LGR5 and CD133 gene expression. j PC/AA/C1- and k LS174T-derived spheroids after 21 days of treatment with 5-ASA. All
mRNA values are normalised to the housekeeping genes TBP or HPRT. Data show relative mRNA quantity of LGR5 and CD133 presented as a
fold change of the control, which itself was normalised to one. Data are presented as the mean of three independent experiments ± SEM;





































































































































































































































Fig. 5 The growth inhibitory effect of 5-ASA on PC/AA/C1 adenoma- and LS174T carcinoma-derived spheroids is sustained for 14 days
after treatment is stopped. a–d PC/AA/C1 human adenoma-derived cells. a Mean number of spheroids per well after 7 days in culture. n= 3
± SEM; *p < 0.05. b Mean log spheroid area over 21 days in culture. 5-ASA was withdrawn from the culture media on day 7. n= 3 ± SEM. c Log
spheroid area after 21 days in culture, demonstrating distribution of spheroid size. n= 1 ± SD (representative of n= 3). d Mean log spheroid
area of spheroids at day 21. n= 3 ± SEM; **p < 0.01. e–h LS174T human carcinoma-derived cells. e Mean number of spheroids per well after
7 days in culture. n= 3 ± SEM. f Mean log spheroid area over 21 days in culture. 5-ASA was withdrawn from the culture media on day 7. n= 3
± SEM. g Log spheroid area after 21 days in culture, demonstrating distribution of spheroid size. n= 1 ± SD (representative of n= 3). h Mean
log spheroid area of spheroids at day 21. n= 3 ± SEM; *p < 0.05; **p < 0.01.
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